6-chloro-2-ethyl-3-pyridinecarbonitrile | 1150103-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-chloro-2-ethyl-3-pyridinecarbonitrile
• 英文别名: 6-Chloro-2-ethylnicotinonitrile；6-chloro-2-ethylpyridine-3-carbonitrile
• CAS: 1150103-22-2
• 化学式: C₈H₇ClN₂
• mdl: MFCD18803154
• 分子量: 166.61
• InChiKey: XXOOADFBVXHURU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-chloro-2-ethyl-3-pyridinecarbonitrile 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 生成
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF

  摘要：

  Provided herein are novel compounds, for example, compounds having a Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound having a Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KIF18A in a cell, and/or in treating various cancers associated with KIF18A protein.

  公开号：

  WO2024109923A1
• 作为产物：
  描述：

  6-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-methyl-3-pyridinecarbonitrile 在 lithium diisopropyl amide 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 2.83h， 生成 6-chloro-2-ethyl-3-pyridinecarbonitrile
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF

  摘要：

  Provided herein are novel compounds, for example, compounds having a Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound having a Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KIF18A in a cell, and/or in treating various cancers associated with KIF18A protein.

  公开号：

  WO2024109923A1

文献信息

• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009058921A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及在治疗与CCR5相关的疾病和紊乱中有用的化合物，例如，在抑制HIV复制、预防或治疗HIV感染以及治疗由此导致的获得性免疫缺陷综合症（AIDS）方面有用的化合物。
• AFFINITY MATRIX LIBRARY AND ITS USE
  申请人：LI Rongxiu

  公开号：US20090240033A1

  公开（公告）日：2009-09-24

  The invention relates, at least in part, to an affinity matrix library and the construction and use thereof. The library may be used, for example, for the enrichment of low-abundance proteins and depletion of abundant proteins in the search for biologically important proteins. The present invention also relates to a synthetic affinity matrix library comprising one or more ligand compounds with groups selected from amino, sulfhydryl, hydroxyl, carbonyl, and/or active hydrogen. The ligand compound may be attached to a base matrix.
• US3957860A
  申请人：——

  公开号：US3957860A

  公开（公告）日：1976-05-18
• US5602237A
  申请人：——

  公开号：US5602237A

  公开（公告）日：1997-02-11